MSLN and neoplasm: We selected the PD1TM version of the CSR for its greater sensitivity to regulation by PD-L1 levels, which we believe reduces the risk of cytokine release syndrome and on-target/off-tumor toxicity, and integrated this with the anti-MSLN TRuC utilized in TC-210 to create a second-generation TRuC-T cell product that we call TC-510.